Stay updated on Cabozantinib vs Paclitaxel in Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib vs Paclitaxel in Ovarian Cancer Clinical Trial page.

Latest updates to the Cabozantinib vs Paclitaxel in Ovarian Cancer Clinical Trial page
- Check6 days agoChange DetectedRevision updated to v3.4.3 (from v3.4.2).SummaryDifference0.0%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check34 days agoChange DetectedThe page adds a reference to Primary peritoneal carcinoma and a Genetic and Rare Diseases Information Center resource, and removes the government funding notice. A revision note (v3.4.2) is also shown.SummaryDifference0.2%

- Check41 days agoChange DetectedA site-wide notice about funding-related delays was added, and the page revision was updated from v3.4.0 to v3.4.1.SummaryDifference0.2%

- Check48 days agoChange DetectedAdded a glossary toggle and updated footer/labels to reflect QC status and version (Last Update Submitted that Met QC Criteria, No FEAR Act Data, Revision: v3.4.0). Removed older labels (Last Update Submitted that met QC Criteria, No FEAR Act data, Revision: v3.3.4).SummaryDifference0.1%

- Check62 days agoChange DetectedThe page footer now shows Revision: v3.3.4, replacing the earlier Revision: v3.3.3. No study content, enrollment data, or results are affected. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check84 days agoChange DetectedAdded a comprehensive Locations section listing study sites by state (Alabama through Wisconsin) with revision tag v3.3.3.SummaryDifference1%

Stay in the know with updates to Cabozantinib vs Paclitaxel in Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib vs Paclitaxel in Ovarian Cancer Clinical Trial page.